Brain metabolite levels in remitted psychotic depression with consideration of effects of antipsychotic medication
-
Published:2023-11-02
Issue:
Volume:
Page:
-
ISSN:1931-7557
-
Container-title:Brain Imaging and Behavior
-
language:en
-
Short-container-title:Brain Imaging and Behavior
Author:
Tani Hideaki,Moxon-Emre Iska,Forde Natalie J.,Neufeld Nicholas H.,Bingham Kathleen S.,Whyte Ellen M.,Meyers Barnett S.,Alexopoulos George S.,Hoptman Matthew J.,Rothschild Anthony J.,Uchida Hiroyuki,Flint Alastair J.,Mulsant Benoit H.,Voineskos Aristotle N.
Abstract
Abstract
Background
The neurobiology of psychotic depression is not well understood and can be confounded by antipsychotics. Magnetic resonance spectroscopy (MRS) is an ideal tool to measure brain metabolites non-invasively. We cross-sectionally assessed brain metabolites in patients with remitted psychotic depression and controls. We also longitudinally assessed the effects of olanzapine versus placebo on brain metabolites.
Methods
Following remission, patients with psychotic depression were randomized to continue sertraline + olanzapine (n = 15) or switched to sertraline + placebo (n = 18), at which point they completed an MRS scan. Patients completed a second scan either 36 weeks later, relapse, or discontinuation. Where water-scaled metabolite levels were obtained and a Point-RESolved Spectroscopy sequence was utilized, choline, myo-inositol, glutamate + glutamine (Glx), N-acetylaspartate, and creatine were measured in the left dorsolateral prefrontal cortex (L-DLPFC) and dorsal anterior cingulate cortex (dACC). An ANCOVA was used to compare metabolites between patients (n = 40) and controls (n = 46). A linear mixed-model was used to compare olanzapine versus placebo groups.
Results
Cross-sectionally, patients (compared to controls) had higher myo-inositol (standardized mean difference [SMD] = 0.84; 95%CI = 0.25–1.44; p = 0.005) in the dACC but not different Glx, choline, N-acetylaspartate, and creatine. Longitudinally, patients randomized to placebo (compared to olanzapine) showed a significantly greater change with a reduction of creatine (SMD = 1.51; 95%CI = 0.71–2.31; p = 0.0002) in the dACC but not glutamate + glutamine, choline, myo-inositol, and N-acetylaspartate.
Conclusions
Patients with remitted psychotic depression have higher myo-inositol than controls. Olanzapine may maintain creatine levels. Future studies are needed to further disentangle the mechanisms of action of olanzapine.
Funder
Canadian Institutes of Health Research National Institute of Mental Health
Publisher
Springer Science and Business Media LLC
Subject
Behavioral Neuroscience,Psychiatry and Mental health,Cellular and Molecular Neuroscience,Neurology (clinical),Cognitive Neuroscience,Neurology,Radiology, Nuclear Medicine and imaging
Reference50 articles.
1. Albert, K. A., Hemmings, H. C., Jr., Adamo, A. I., Potkin, S. G., Akbarian, S., Sandman, C. A., Cotman, C. W., Bunney, W. E., Jr., & Greengard, P. (2002). Evidence for decreased DARPP-32 in the prefrontal cortex of patients with schizophrenia. Archives of General Psychiatry, 59(8), 705–712. https://doi.org/10.1001/archpsyc.59.8.705 2. Bingham, K. S., Calarco, N., Dickie, E. W., Alexopoulos, G. S., Butters, M. A., Meyers, B. S., Marino, P., Neufeld, N. H., Rothschild, A. J., Whyte, E. M., Mulsant, B. H., Flint, A. J., & Voineskos, A. N. (2023). The relationship of white matter microstructure with psychomotor disturbance and relapse in remitted psychotic depression. Journal of Affective Disorders, 334, 317–324. https://doi.org/10.1016/j.jad.2023.04.136 3. Brand, A., Richter-Landsberg, C., & Leibfritz, D. (1993). Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Developmental Neuroscience, 15(3–5), 289–298. https://doi.org/10.1159/000111347 4. Busatto, G. F. (2013). Structural and functional neuroimaging studies in major depressive disorder with psychotic features: a critical review. Schizophrenia Bulletin, 39(4), 776–786. https://doi.org/10.1093/schbul/sbt054 5. Chang, K., Delbello, M., Chu, W. J., Garrett, A., Kelley, R., Mills, N., Howe, M., Bryan, H., Adler, C., Eliassen, J., Spielman, D., & Strakowski, S. M. (2012). Neurometabolite effects of response to quetiapine and placebo in adolescents with bipolar depression. Journal of Child and Adolescent Psychopharmacology, 22(4), 261–268. https://doi.org/10.1089/cap.2011.0153
|
|